Bruno Bastos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bruno Bastos has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Pamela N. Munster
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California
88 shared publications - Andrew L. Coveler
Fred Hutchinson Cancer Center Seattle Washington USA
57 shared publications - Andrew P. Mazar
Actuate Therapeutics, Inc., Fort Worth, Texas
57 shared publications - Andrés Cervantes
INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
57 shared publications - Anwaar Saeed
Department of Medicine, Division of Hematology & Medical Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA
57 shared publications - Austin Koukol
18Actuate Therapeutics, Fort Worth, Texas
57 shared publications
Latest Publications
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Tumor profile association with OS. A, Association of OS in tumors with the top 75th percentile of B7-H3 expression (relative to all cancers) across 50 tumor types. *, q < 0.05; **, q < 0.01; ***, q < 0.001. B, OS of patients with high B7-H3 expression compared with low B7-H3 expression (stratified on the basis of medians) for the top six cancers where CD276-high expression is associated with poor OS. Cox proportional HRs were calculated for each comparison group with significance determined as P values of <0.05 using log-rank statistics. C, OS of patients with high B7-H3 expression compared with low B7-H3 expression (stratification based on quartiles) from the start of pembrolizumab treatment for patients with colorectal cancer with microsatellite instability (CRC-MSI-H), NSCLC-adenocarcinoma (NSCLC-Ad) that is PD-L1–positive/EGFR wildtype/ALK wildtype, and NSCLC-squamous (NSCLC-Sq) cell carcinoma that is PD-L1 positive.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Tumor profile association with OS. A, Association of OS in tumors with the top 75th percentile of B7-H3 expression (relative to all cancers) across 50 tumor types. *, q < 0.05; **, q < 0.01; ***, q < 0.001. B, OS of patients with high B7-H3 expression compared with low B7-H3 expression (stratified on the basis of medians) for the top six cancers where CD276-high expression is associated with poor OS. Cox proportional HRs were calculated for each comparison group with significance determined as P values of <0.05 using log-rank statistics. C, OS of patients with high B7-H3 expression compared with low B7-H3 expression (stratification based on quartiles) from the start of pembrolizumab treatment for patients with colorectal cancer with microsatellite instability (CRC-MSI-H), NSCLC-adenocarcinoma (NSCLC-Ad) that is PD-L1–positive/EGFR wildtype/ALK wildtype, and NSCLC-squamous (NSCLC-Sq) cell carcinoma that is PD-L1 positive.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Independence of B7-H3 expression and immunotherapy biomarkers. Alteration frequency of TMB-high (A), MSI-high (B), MMRd (C), and PD-1/ PD-L1 status (D) across 11 different cancer types with high and low B7-H3 expression, including prostate cancer from a primary site (PRAD-Prostate), prostate cancer from a metastatic site (PRAD-Metastatic), colorectal cancer with microsatellite stability (CRC-MSS), colorectal cancer with microsatellite instability (CRC-MSI), non–small cell lung adenocarcinoma (NSCLC-Ad), non–small cell lung squamous carcinoma (NSCLC-Sq), triple-negative breast cancer (BRCA-TNBC), hormone receptor–positive/HER2-negative breast cancer (BRCA-HR+/HER2−), HER2-positive breast cancer (BRCA-HER2+), ovarian surface epithelial carcinoma (OSEC), and pancreatic carcinoma (PDAC). *, q < 0.05; **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Independence of B7-H3 expression and immunotherapy biomarkers. Alteration frequency of TMB-high (A), MSI-high (B), MMRd (C), and PD-1/ PD-L1 status (D) across 11 different cancer types with high and low B7-H3 expression, including prostate cancer from a primary site (PRAD-Prostate), prostate cancer from a metastatic site (PRAD-Metastatic), colorectal cancer with microsatellite stability (CRC-MSS), colorectal cancer with microsatellite instability (CRC-MSI), non–small cell lung adenocarcinoma (NSCLC-Ad), non–small cell lung squamous carcinoma (NSCLC-Sq), triple-negative breast cancer (BRCA-TNBC), hormone receptor–positive/HER2-negative breast cancer (BRCA-HR+/HER2−), HER2-positive breast cancer (BRCA-HER2+), ovarian surface epithelial carcinoma (OSEC), and pancreatic carcinoma (PDAC). *, q < 0.05; **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Association of B7-H3 expression and common hallmark mRNA signatures. GSEA with functional oncogenic pathways on several tumor types with high and low B7-H3 expression. Normalized enrichment scores are displayed. FDR < 0.05 based on values between −3 and 3. Boxes marked with “X” indicate that the enrichment of the pathway did not meet thresholds of significance in the tumor type.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Association of B7-H3 expression and common hallmark mRNA signatures. GSEA with functional oncogenic pathways on several tumor types with high and low B7-H3 expression. Normalized enrichment scores are displayed. FDR < 0.05 based on values between −3 and 3. Boxes marked with “X” indicate that the enrichment of the pathway did not meet thresholds of significance in the tumor type.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Independence of B7-H3 expression and immunotherapy biomarkers. Alteration frequency of TMB-high (A), MSI-high (B), MMRd (C), and PD-1/ PD-L1 status (D) across 11 different cancer types with high and low B7-H3 expression, including prostate cancer from a primary site (PRAD-Prostate), prostate cancer from a metastatic site (PRAD-Metastatic), colorectal cancer with microsatellite stability (CRC-MSS), colorectal cancer with microsatellite instability (CRC-MSI), non–small cell lung adenocarcinoma (NSCLC-Ad), non–small cell lung squamous carcinoma (NSCLC-Sq), triple-negative breast cancer (BRCA-TNBC), hormone receptor–positive/HER2-negative breast cancer (BRCA-HR+/HER2−), HER2-positive breast cancer (BRCA-HER2+), ovarian surface epithelial carcinoma (OSEC), and pancreatic carcinoma (PDAC). *, q < 0.05; **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Independence of B7-H3 expression and immunotherapy biomarkers. Alteration frequency of TMB-high (A), MSI-high (B), MMRd (C), and PD-1/ PD-L1 status (D) across 11 different cancer types with high and low B7-H3 expression, including prostate cancer from a primary site (PRAD-Prostate), prostate cancer from a metastatic site (PRAD-Metastatic), colorectal cancer with microsatellite stability (CRC-MSS), colorectal cancer with microsatellite instability (CRC-MSI), non–small cell lung adenocarcinoma (NSCLC-Ad), non–small cell lung squamous carcinoma (NSCLC-Sq), triple-negative breast cancer (BRCA-TNBC), hormone receptor–positive/HER2-negative breast cancer (BRCA-HR+/HER2−), HER2-positive breast cancer (BRCA-HER2+), ovarian surface epithelial carcinoma (OSEC), and pancreatic carcinoma (PDAC). *, q < 0.05; **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Characterization of B7-H3 expression in tumors. B7-H3 transcripts per million (TPM) after log normalization. A total of 156,791 samples from 50 distinct tumor types were analyzed from the Precision Oncology Alliance (POA) consortium. Data shown in violin plots in which the white dot represents the median and the black box shows the ends of the first and third quartiles. The female genital tract malignancy category represents sarcomas from gynecologic sites and the male genital tract malignancy category represents primarily testicular cancer.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Characterization of B7-H3 expression in tumors. B7-H3 transcripts per million (TPM) after log normalization. A total of 156,791 samples from 50 distinct tumor types were analyzed from the Precision Oncology Alliance (POA) consortium. Data shown in violin plots in which the white dot represents the median and the black box shows the ends of the first and third quartiles. The female genital tract malignancy category represents sarcomas from gynecologic sites and the male genital tract malignancy category represents primarily testicular cancer.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
B7-H3 mRNA expression across cancers stratified by age (>/< 65 years old) and sex (male and female)
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
B7-H3 mRNA expression across cancers stratified by age (>/< 65 years old) and sex (male and female)
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
B7-H3 expression and immune cell landscape. Immune cell deconvolution using quanTIseq demonstrates differences in cell fraction of T cells CD8+ (A), macrophage M1 (B), and macrophage M2 (C) across 10 different cancer types with high and low B7-H3 expression. *, q < 0.05; **, q < 0.01; ***, q < 0.001.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
B7-H3 expression and immune cell landscape. Immune cell deconvolution using quanTIseq demonstrates differences in cell fraction of T cells CD8+ (A), macrophage M1 (B), and macrophage M2 (C) across 10 different cancer types with high and low B7-H3 expression. *, q < 0.05; **, q < 0.01; ***, q < 0.001.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Association of B7-H3 expression and common hallmark mRNA signatures. GSEA with functional oncogenic pathways on several tumor types with high and low B7-H3 expression. Normalized enrichment scores are displayed. FDR < 0.05 based on values between −3 and 3. Boxes marked with “X” indicate that the enrichment of the pathway did not meet thresholds of significance in the tumor type.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Association of B7-H3 expression and common hallmark mRNA signatures. GSEA with functional oncogenic pathways on several tumor types with high and low B7-H3 expression. Normalized enrichment scores are displayed. FDR < 0.05 based on values between −3 and 3. Boxes marked with “X” indicate that the enrichment of the pathway did not meet thresholds of significance in the tumor type.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Association of B7-H3 expression with key driver mutations. Alteration frequency of TP53 mutations (A), RB1 mutations (B), KRAS mutations (C), MYC amplifications (D) of across 10 different cancer types with high and low B7-H3 expression. **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Association of B7-H3 expression with key driver mutations. Alteration frequency of TP53 mutations (A), RB1 mutations (B), KRAS mutations (C), MYC amplifications (D) of across 10 different cancer types with high and low B7-H3 expression. **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.
- Open Access
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
B7-H3 mRNA expression across cancers stratified by age (>/< 65 years old) and sex (male and female)
- 30 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
B7-H3 mRNA expression across cancers stratified by age (>/< 65 years old) and sex (male and female)